Humira

Common Uses

Humira is primarily used to treat autoimmune and inflammatory disorders. It is often prescribed when other treatments have not been effective enough in managing symptoms.

Joint and Bone Conditions

• Rheumatoid arthritis: Used in adults to reduce pain, swelling, and joint damage in moderate to severe cases.
• Juvenile idiopathic arthritis: Used in children ages 2 and older to manage moderate to severe symptoms.
• Psoriatic arthritis: Used to reduce joint pain and improve physical function in adults.
• Ankylosing spondylitis: Used to reduce inflammation and symptoms in the spine and joints of adults.

Skin Conditions

• Plaque psoriasis: Prescribed for adults with chronic moderate to severe disease who are candidates for systemic therapy or phototherapy.
• Hidradenitis suppurativa: Used to treat moderate to severe cases of this chronic skin condition in adults and adolescents ages 12 and older.

Digestive System Conditions

• Crohn's disease: Used for adults and children ages 6 and older with moderate to severe disease to help achieve and maintain remission.
• Ulcerative colitis: Used for adults with moderate to severe disease when certain other medicines have not worked well enough.

Eye Conditions

Humira is used to treat certain types of non-infectious uveitis, which is inflammation that affects the middle layer of the eye, in adults and children ages 2 and older.

Targeting Inflammation

Humira belongs to a class of drugs known as tumor necrosis factor (TNF) blockers. TNF is a protein naturally produced by the body's immune system. While it normally helps the body fight infections, people with certain autoimmune diseases produce too much of it, leading to chronic inflammation.

How Adalimumab Works

The active ingredient in Humira, adalimumab, is a monoclonal antibody. It is designed to recognize and bind to TNF-alpha proteins in the blood and tissues. By attaching to these proteins, the medication prevents them from connecting to receptors on healthy cells and triggering the inflammatory response.

Effects on the Body

By reducing the activity of TNF, Humira helps to manage symptoms and prevent long-term damage. Its primary actions include:

• Decreasing swelling and pain in the joints.
• Reducing skin inflammation and the formation of plaques.
• Lowering inflammation in the digestive tract.
• Slowing or preventing permanent damage to bones and cartilage.

Because this medication works by suppressing a specific part of the immune system to control inflammation, it may also affect the body's natural ability to fight off certain types of infections.

Common Side Effects

Many people using Humira experience mild side effects. These often include:

• Pain, redness, itching, or swelling at the injection site
• Headache
• Rash
• Nausea
• Back pain

Serious Side Effects

Some side effects require immediate medical attention. Contact a healthcare provider right away if you notice:

• Signs of infection: Fever, chills, body aches, or a persistent cough.
• Allergic reactions: Hives, swelling of the face, lips, or tongue, and trouble breathing.
• Nervous system issues: Numbness, tingling, weakness in the legs, or vision changes.
• Heart problems: Shortness of breath with exertion or while lying down, and swelling of the ankles or feet.
• Liver issues: Yellowing of the eyes or skin, dark urine, or pain on the right side of the stomach area.
• Lupus-like syndrome: Joint pain or a rash on the cheeks or arms that is sensitive to sunlight.

Serious Infections

Humira can lower the body's ability to fight infections. Some people have developed serious infections while taking this medication, including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria. These infections may lead to hospitalization or death. Testing for TB is required before starting treatment, and monitoring for signs of infection typically continues throughout therapy.

Cancer Risks

There is an increased risk of lymphoma and other cancers in children and adults taking TNF blockers. A rare and serious type of cancer called hepatosplenic T-cell lymphoma has been reported, primarily in adolescent and young adult males with Crohn's disease or ulcerative colitis who were also taking other specific immune-suppressing medications.

Hepatitis B Reactivation

For individuals who are carriers of the hepatitis B virus, the virus can become active again during treatment. This may cause serious liver problems and can be fatal. Healthcare providers monitor liver function and viral status in these cases before and during treatment.

Neurological and Blood Disorders

Humira has been associated with rare cases of nervous system problems, such as multiple sclerosis and Guillain-Barré syndrome. Additionally, some patients may experience a significant drop in blood cell counts, which can affect the body's ability to clot or fight new infections.

Additional Precautions

• Heart Failure: This medication may cause new or worsening symptoms of heart failure.
• Liver Injury: Severe liver reactions have occurred, which may lead to liver failure in rare instances.
• Lupus-like Syndrome: Some patients develop symptoms similar to lupus, which typically resolve after the medication is discontinued.
• Vaccines: Live vaccines should not be administered while using this medication.
• Hypersensitivity: Serious allergic reactions, including anaphylaxis, are possible and require immediate medical attention.

Pregnancy

Research on the use of Humira during pregnancy is ongoing. Current evidence suggests that the medication does not appear to increase the risk of major birth defects. However, adalimumab (the active ingredient in Humira) can cross the placenta, particularly during the third trimester. This exposure could potentially affect the immune system of the newborn.

If you use Humira during pregnancy, it is important to inform your child's pediatrician. The timing of certain vaccinations, especially live vaccines like the rotavirus vaccine, may need to be delayed for the infant to ensure their immune system can respond safely.

Breastfeeding

Humira is known to pass into breast milk in very small amounts. Because adalimumab is a large protein molecule, it is generally believed that most of the drug is broken down in the infant's digestive system before it can be absorbed into their bloodstream. Most clinical experts consider breastfeeding while taking Humira to be low risk, but you should discuss your specific situation with your doctor.

Clinical Consultation

If you are pregnant, planning to become pregnant, or breastfeeding, talk to your healthcare team about:

• The severity of your condition and the risks of stopping treatment.
• The potential effects of the medication on the developing fetus or nursing infant.
• The timing of infant vaccinations if the drug was used during the third trimester.

Available Forms

Humira is supplied as a sterile, preservative-free solution for injection under the skin. It is available in the following delivery systems:

• Single-dose pre-filled pen: Designed for self-administration, this device automates the injection process.
• Single-dose pre-filled syringe: A syringe with a fixed needle, used for manual injection by a patient, caregiver, or healthcare provider.
• Single-dose vial: A glass vial containing the solution, intended for use with a separate syringe, often used in clinical settings or for specific pediatric needs.

FDA Approval and Indications

Humira (adalimumab) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of various autoimmune and inflammatory disorders. These include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and certain types of uveitis.

Boxed Warning

The FDA requires a boxed warning for Humira due to the risk of serious infections and malignancy. This is the most serious type of warning issued by the FDA.

• Serious Infections: Patients taking Humira are at an increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial sepsis, and invasive fungal infections.
• Malignancy: Lymphoma and other cancers, some fatal, have been reported in children and adolescent patients treated with TNF blockers like Humira. A rare type of cancer called hepatosplenic T-cell lymphoma has occurred in young adults with inflammatory bowel disease using these medications.

Regulatory Monitoring

The FDA monitors the safety of Humira through post-marketing surveillance. Healthcare providers are required to screen patients for tuberculosis and other infections before starting treatment and monitor them closely during therapy for signs of infection or unusual growths.

Factors Influencing Cost

Several factors determine the final price a patient pays for Humira:

• Insurance Coverage: Most commercial insurance plans and Medicare Part D cover Humira, though it is often placed on a higher specialty tier requiring a significant co-pay or coinsurance.
• Prior Authorization: Insurance companies typically require a prior authorization process, where a healthcare provider must justify the medical necessity of the drug before coverage is approved.
• Pharmacy Choice: Humira is a specialty medication and is usually dispensed through specialty pharmacies rather than standard retail locations.

Financial Assistance and Savings

To help manage out-of-pocket expenses, several programs may be available:

• Co-pay Cards: The manufacturer offers a savings card for patients with commercial (private) insurance, which can significantly reduce monthly costs for eligible individuals.
• Patient Assistance Programs: For individuals without insurance or those who meet specific income requirements, manufacturer-sponsored patient assistance programs may provide the medication at no cost.
• Biosimilars: Several FDA-approved biosimilars for adalimumab are available. These medications are highly similar to Humira and may be offered at a lower price point depending on the insurance formulary.

Patients are encouraged to contact their insurance provider and the manufacturer to explore the most current pricing and assistance options available to them.